The recently announced merger of Thermo Electron Corporation (Waltham, MA, http://www.thermoelectron.com/) and Fisher Scientific International Inc. (Hampton, NH, http://www.fisherscientific.com/) will create a "category killer" in the laboratory supplies business. The $9-billion (revenues) company, which will be named Thermo Fisher Scientific, will combine Thermo Electron's offerings in laboratory equipment and software (including the "Nautilus LIMS" system) with Fisher's huge catalog of supplies, including glassware, chemicals, and other consumables.
Fisher Scientific has been a major driver of consolidation of the laboratory supplies industry in recent years. Its major acquisitions include the 2003 purchase of Perbio for $733 million, the 2004 acquisition of Apogent Technologies for $3.9 billion, and the 2004 purchase of Oxoid for $330 million. It also has made several smaller acquisitions such as Dharmacon for $80 million in 2004 and Cellomics for $49 million in 2005.Thermo and Fisher aren't the only companies consolidating the laboratory supplies space. Millipore Corporation (Billerica, MA, http://www.millipore.com/) announced in April that it is buying Serologicals Corporation (Atlanta, GA, http://www.serologicals.com/) for $1.4 billion. Millipore is a major provider of bioprocess technologies for DNA- and cell-based research and biomanufacturing based upon its expertise in filtration and membrane technologies. Serologicals's line of reagent products, cell-culture media, and assays also is used in the research and biomanufacturing segments. The combined companies will have revenues of $1.4 billion and have 5800 employees.
Private-equity investors also are jumping into the research consumables market. Two venture capital firms, Grotech Capital and Ferrer Freeman & Company, announced in April that they are committing nearly $100 million to back Pelican Life Sciences (Huntersville, NC, http://www.pelicanls.com/), a new entity that is acquiring research companies. Pelican already made its first acquisition, PML Microbiologicals Inc., a maker of microbiological products such as culture media, and plans to make more in pursuit of a classic "roll-up" strategy that is popular in private-equity investing. Pelican executives are laboratory supplies industry veterans: CEO Bill Baugh was president of Global Laboratory Products for Fisher Scientific International, and president Jeff Leathe was the chief financial officer of Apogent Technologies.
The rationales for the M&A activity in the laboratory supplies market are straightforward: economies of scale, synergies from cross-marketing of products, and clout in the procurement process. The combined companies will have large sales forces—7500 for Thermo Fisher Scientific, 1200 for Millipore—that will have much-expanded product lines to promote to their customers. One of the strengths of these combinations is that the merging companies have little duplication in their product offerings because one party is focused on instruments while the other is focused on consumables. The companies also expect significant cost savings: $200 million a year in the case of Thermo Fisher Scientific and $17 million annually for Millipore on a smaller cost base.
The merged companies are likely to enjoy big advantages in the procurement departments of major pharmaceutical companies. With the size of their catalogs and the volume of business they generate, the companies will be in unrivaled positions to negotiate preferred vendor deals. Deeply discounted pricing will be a major feature of those deals, but there probably will be other features that will tie the customer and the vendor closely together, including customized online catalogs, online buying, and reports on commodity usage that will help customers manage costs over time.